Other Clinical Trial - Effect on Tumor Perfusion of a Chemotherapy

Status Completed

Clinical Trial Summary

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with conventional treatments having little impact on disease course. Novel approaches are urgently needed to address inherent resistance to the current therapies and to identify new drugs or combinations that will have a high chance of success in pancreatic cancer patients. This proof-of-concept trial is studying the "dynamic" tumor response after the administration of a short course of gemcitabine and nab-paclitaxel (Abraxane) (a) during a window interval (4 weeks= 1 cycle) before surgery in resectable pancreatic cancer (cohort 1 = 21 patients) and (b) during at least 8 weeks (2 cycles) in locally advanced or metastatic pancreatic cancer (cohort 2 = 10 patients).

Clinical Trial Description

Pancreatic cancer is a hypoperfused tumor, characterized by a high stroma density precluding cytotoxics delivery to the epithelial tumoral compartment. There is thus a rationale for combining chemotherapy and antistromal drugs like nab-paclitaxel (Abraxane), a solvent (Cremophor® EL)-free, albumin-bound form of paclitaxel that has been initially developed to reduce the toxicities associated with Taxol injection while maintaining or improving its chemotherapeutic effect. This unique protein formulation provides a novel approach of increasing intra-tumoral concentrations of the drug by a receptor-mediated transport process allowing transcytosis across the endothelial cell.

Abraxane has been approved for commercialization in 38 countries, including the US, Canada, the EU, Australia, China, India and Korea for the treatment of women with metastatic breast cancer. Abraxane alone and in combination is being evaluated in a number of cancers, including metastatic melanoma, non-small cell lung cancer, pancreatic cancer and other solid tumors. ;

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Pancreatic Adenocarcinoma Locally Advanced
Pancreatic Adenocarcinoma Metastatic
Pancreatic Adenocarcinoma Resectable

Clinical Trial Details

NCT number	NCT01715142
Study type	Interventional
Source	Erasme University Hospital
Contact
Status	Completed
Phase	Early Phase 1
Start date	March 21, 2013
Completion date	April 30, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06006728` - Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
Terminated	`NCT03213626` - Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma	Phase 2
Recruiting	`NCT05077800` - FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer	Phase 2
Completed	`NCT02179970` - To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers	Phase 1
Completed	`NCT02195180` - Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma	Phase 2
Recruiting	`NCT06051851` - Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer	Phase 2
Recruiting	`NCT03633734` - Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma	Phase 1/Phase 2
Completed	`NCT03529175` - Scheduling Nab-paclitaxel With Gemcitabine	Phase 2
Recruiting	`NCT05360264` - tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr	Phase 2
Recruiting	`NCT04150042` - SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells	Phase 1
Withdrawn	`NCT03127124` - QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT06076837` - The Seven Trial: Exploiting the Unfolded Protein Response	Phase 1
Recruiting	`NCT06396637` - PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC	Phase 2
Completed	`NCT01053013` - Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer — NEOPAX-001

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms